2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Thursday, March 19, 2026

6:00PM-7:00PM: Abstract Number: 034

Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Management Across Countries: A Survey to Inform Future Comparative Effectiveness Research

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 064

Recognizing Paradoxical Psoriasis in TNF-Inhibitor–Treated Pediatric Rheumatic Disease: A Saskatchewan Experience

Posters: Quality, Health Services, and Education Research I

6:00PM-7:00PM: Abstract Number: 055

Referrals Leading to Rheumatologic Diagnosis in a Pediatric Rheumatology Center: Influence of Referring Provider Practice and Training

Posters: Quality, Health Services, and Education Research I

6:00PM-7:00PM: Abstract Number: 065

Screening for Social Determinants of Health Identifies Differences Based on Insurance Types in a Single Pediatric Rheumatology Division

Posters: Quality, Health Services, and Education Research I

6:00PM-7:00PM: Abstract Number: 023

Screening Tools for Spondyloarthropathies among Patients with Inflammatory Bowel Disease: A Scoping Review

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 039

Single-center Experience of Voclosporin Use for Pediatric Lupus Nephritis

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 072

SOCS1 Haploinsufficiency: Functional Evidence Supporting an Expanded Clinical Phenotype

Posters: Genetics and Pathogenesis I

6:00PM-7:00PM: Abstract Number: 067

Standardizing Effective Education and Intervention for Chronic Non-Inflammatory Pain in Children with Juvenile Idiopathic Arthritis: A Quality Improvement Initiative

Posters: Quality, Health Services, and Education Research I

6:00PM-7:00PM: Abstract Number: 016

Still’s Disease Associated Lung Disease: Experience from a Tertiary Italian Centre

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 007

Subtle Signs, Severe Consequences: Clinical profile of infants with giant coronary aneurysms compared to those with normal coronaries. A multicentric retrospective analysis of infants with Kawasaki disease

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 071

The Association Between Age at Diagnosis and Health-Related Quality of Life in Takayasu Arteritis

Posters: Special Category: Patient Engagement

6:00PM-7:00PM: Abstract Number: 069

The Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis trial: Baseline cohort characteristics and importance of stakeholder partner-informed knowledge translation and exchange

Posters: Special Category: Patient Engagement

6:00PM-7:00PM: Abstract Number: 050

The Quiet Beginning: Early Pediatric Systemic Lupus Erythematosus (SLE) Without Nephritis and the Path to Renal Involvement

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 024

Therapeutic Plasma Exchange in Pediatric Autoimmune Encephalitis

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 074

Tissue Protein Expression Profiling of Interferon Gamma and Frizzled-Wnt-related Signaling Show Increased Periadnexal and Perivascular Localization in Juvenile Localized Scleroderma Skin

Posters: Genetics and Pathogenesis I

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].